People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capstan Therapeutics, Inc. | — | Biotechnology | Series C | $227.0M | $882.9M | 2021 |
Priya Karmali at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Priya Karmali on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Erez Chimovits | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Laura Shawver | 1 | 6 |
| Michael Baran | 1 | 4 |
| Nandita Shangari | 1 | 4 |
| Ramin Farzaneh-Far | 1 | 3 |
| Rajul Jain | 1 | 3 |
| Athena Countouriotis | 1 | 2 |
| Fabio Pucci | 1 | 2 |
| Nanna Luneborg | 1 | 2 |
| Karen Smith | 1 | 1 |
| Justin Thacker | 1 | 1 |
| Adrian Bot | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.